Naproxcinod is the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class, which NicOx S/A aims to establish as the drug-of-choice for the treatment of osteoarthritis.
According to Thomas J. Schnitzer, MD, PhD, Professor and Assistant Dean for Clinical Research at Northwestern University and Principal Investigator on the trial:
"The positive outcome of this pivotal trial for naproxcinod is an important step towards making this an efficacious and potentially safer treatment option for osteoarthritis patients.Compared to placebo, the two naproxcinod doses (375 mg bid and 750 mg bid) proved to be superior in treating the signs and symptoms of osteoarthritis.
The blood pressure data showing a clear improvement against naproxen and from baseline is also extremely encouraging, in the light of the considerable need for a non-steroidal anti-inflammatory drug with an improved blood pressure profile."
Find more details of the clinical study results from the press release (a pdf file).
Comment Preview